Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

363
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
363
Tumor Immunotherapy01:27

Tumor Immunotherapy

523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Vaccinations01:51

Vaccinations

44.5K
Overview
44.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retina-specific long non-coding RNAs associated with inherited retinal disease genes.

Cellular and molecular life sciences : CMLS·2026
Same author

Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy.

Nature communications·2026
Same author

Single-cell mapping of alternative splicing linked to checkpoint immunotherapy response.

Nucleic acids research·2025
Same author

Accelerating Neoantigen Discovery: A High-Throughput Approach to Immunogenic Target Identification.

Vaccines·2025
Same author

Neoantigen-directed therapeutics in the clinic: where are we?

Trends in cancer·2023
Same author

Challenges in neoantigen-directed therapeutics.

Cancer cell·2022

Related Experiment Video

Updated: Jun 29, 2025

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

11.6K

Methods behind neoantigen prediction for personalized anticancer vaccines.

Kiyana Godazandeh1, Lies Van Olmen1, Lore Van Oudenhove1

  • 1myNEO, Ghent, Belgium.

Methods in Cell Biology
|March 28, 2024
PubMed
Summary

This guide details in-silico neoantigen prediction for personalized cancer immunotherapy. It outlines steps and tools for identifying immunogenic neoantigens, enhancing treatment efficacy.

Keywords:
BioinformaticsNeoantigen detectionPersonalized cancer immunotherapy

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.2K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

Related Experiment Videos

Last Updated: Jun 29, 2025

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

11.6K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.2K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

Area of Science:

  • Oncology
  • Bioinformatics
  • Immunology

Background:

  • Immunotherapies, including immune checkpoint inhibitors, have significantly advanced cancer treatment.
  • Next-generation sequencing and bioinformatics enable the identification of patient-specific immunogenic neoantigens.
  • Neoantigens are crucial targets for developing personalized immunotherapies with improved cancer cell targeting.

Purpose of the Study:

  • To provide a comprehensive, step-by-step protocol for in-silico neoantigen prediction.
  • To discuss the analytical methods and challenges involved in identifying immunogenic neoantigens.
  • To guide researchers in utilizing bioinformatics tools for neoantigen discovery.

Main Methods:

  • Utilizing next-generation sequencing data for neoantigen identification.
  • Applying bioinformatics pipelines for variant calling and mutation annotation.
  • Employing algorithms for predicting neoantigen binding affinity and immunogenicity.
  • Integrating various computational tools for a complete neoantigen prediction workflow.

Main Results:

  • A detailed protocol for in-silico neoantigen prediction is presented.
  • Key analytical steps and potential challenges are highlighted.
  • The study facilitates the identification of patient-specific neoantigens for immunotherapy.

Conclusions:

  • In-silico neoantigen prediction is a vital component of personalized cancer immunotherapy.
  • This protocol offers a standardized approach to neoantigen identification.
  • Accurate neoantigen prediction can lead to more effective and targeted cancer treatments.